Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Inositec
Zurich, Zurich, Switzerlandinositec.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Inositec is developing inositol phosphate–based small molecules against calcification disorders using its Inositune platform. Its lead compound INS-3001 is described as a cardiovascular calcification inhibitor in development for aortic valve stenosis, with available descriptions consistent with pre-clinical to early development status and no publicly reported completed clinical trials yet.[1][2][3]
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Vifor Pharma (acquirer and strategic partner in cardiorenal space)
Beyond the preview
Go deeper on Inositec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inositec.